23599-69-1
23599-69-1
Chemical Structure
Norisoboldine
Synonym(s): (+)-Laurelliptine
- No. CAS: 23599-69-1
- Formula:C18H19NO4
- Molecular Weight:313.35
IUPAC Name: (S)-2,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1,9-diol
InChIKey: HORZNQYQXBFWNZ-LBPRGKRZSA-N
SMILES: OC1=C(OC)C=C2CCN[C@@]3([H])CC4=CC(O)=C(OC)C=C4C1=C23
Biological Activity: Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Norisoboldine | 99.93% | Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Norisoboldine (Standard) | ≥98% | Norisoboldine (Standard) is the analytical standard of Norisoboldine. This product is intended for research and analytical applications. Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Luo Y, et al. Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice. Phytomedicine. 2010;17(10):726-731. [Content Brief]
- [2]. Lv Q, et al. Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD+/SIRT1/SUV39H1/H3K9me3 signaling pathway. Cell Death Dis. 2018;9(3):258. Published 2018 Feb 15. [Content Brief]
